Magnasense 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Marco Wititteveen

최고 경영자

SEK 2.4m

총 보상

CEO 급여 비율	47.2%
CEO 임기	1.4yrs
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO 보상 분석

Marco Wititteveen 의 보수는 Magnasense 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 41m
Mar 31 2024	n/a	n/a	-SEK 49m
Dec 31 2023	SEK 2m	SEK 1m	-SEK 60m

보상 대 시장: Marco 의 총 보상 ($USD 225.22K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 243.28K ).

보상과 수익: Marco 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Marco Wititteveen (55 yo)

1.4yrs

테뉴어

SEK 2,420,854

보상

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023 and serves as its Member of the Board. He has previously had multiple dif...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marco Wititteveen	CEO & Member of the Board	1.4yrs	SEK 2.42m	데이터 없음
Vicki Johnson	Interim Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Vasiliki Fragkou	Chief Operating Officer	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

경험이 풍부한 관리: MAGNA 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Marco Wititteveen	CEO & Member of the Board	no data	SEK 2.42m	데이터 없음
William Ferenczy	Member of the Board	less than a year	데이터 없음	데이터 없음
William Vickery	Independent Director	2.8yrs	SEK 105.00k	데이터 없음
Michael Schwartz	Member of the Board	less than a year	데이터 없음	데이터 없음
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Fredrik Haglund	Independent Member of the Board	4.5yrs	SEK 105.00k	0.38% SEK 31.2k
Jens Umehag	Chairman	no data	데이터 없음	데이터 없음
Adam Cheifetz	Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Melissa Grant	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: MAGNA 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Magnasense 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

Recent updates

New major risk - Shareholder dilution

Magnasense AB Announces Filing of A Patent Application Covering an Advanced Detection System Designed to Improve the Sensitivity and Accuracy of Magnetic Test Strips Using Superparamagnetic Nanoparticles

Less than half of directors are independent

First half 2024 earnings released: kr0.42 loss per share (vs kr1.36 loss in 1H 2023)

Magnasense AB Announces Chief Financial Officer Changes

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

New minor risk - Share price stability

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

New major risk - Negative shareholders equity

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

New minor risk - Share price stability

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

Independent Member of the Board exercised options to buy kr86k worth of stock.

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

New 90-day high: kr30.88

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: kr25.50

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령